Rakesh K Jain

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1231026/publications.pdf

Version: 2024-02-01

689	141,237	97 166	87 360
papers	citations	h-index	g-index

717	717	717	104614
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.	13.7	7,977
2	Photodynamic therapy for cancer. Nature Reviews Cancer, 2003, 3, 380-387.	12.8	5,585
3	Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science, 2005, 307, 58-62.	6.0	4,792
4	Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473, 298-307.	13.7	4,403
5	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	15.2	3,421
6	Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 2010, 7, 653-664.	12.5	2,666
7	Role of HIF-1Î± in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 1998, 394, 485-490.	13.7	2,565
8	Molecular regulation of vessel maturation. Nature Medicine, 2003, 9, 685-693.	15.2	2,260
9	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
10	Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Medicine, 2001, 7, 987-989.	15.2	1,972
11	Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 2004, 10, 145-147.	15.2	1,852
12	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 2007, 11, 83-95.	7.7	1,675
13	Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nature Medicine, 1997, 3, 177-182.	15.2	1,511
14	Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness. American Journal of Pathology, 2000, 156, 1363-1380.	1.9	1,449
15	Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Reviews Drug Discovery, 2011, 10, 417-427.	21.5	1,345
16	Normalization of the Vasculature for Treatment of Cancer and Other Diseases. Physiological Reviews, 2011, 91, 1071-1121.	13.1	1,275
17	Angiogenesis in brain tumours. Nature Reviews Neuroscience, 2007, 8, 610-622.	4.9	1,229
18	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 325-340.	12.5	1,192

#	Article	IF	Citations
19	Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 2014, 26, 605-622.	7.7	1,184
20	Compact high-quality CdSeâ€“CdS coreâ€“shell nanocrystals with narrow emission linewidthsÂandÂsuppressed blinking. Nature Materials, 2013, 12, 445-451.	13.3	1,168
21	Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science, 1997, 276, 1423-1425.	6.0	1,160
22	The role of nitric oxide in tumour progression. Nature Reviews Cancer, 2006, 6, 521-534.	12.8	1,099
23	Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors. Cancer Research, 2004, 64, 3731-3736.	0.4	1,078
24	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology, 2006, 3, 24-40.	4.3	968
25	Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2426-2431.	3.3	938
26	Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature Nanotechnology, 2012, 7, 383-388.	15.6	928
27	Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers. Journal of Clinical Oncology, 2013, 31, 2205-2218.	0.8	925
28	The bloodâ€“brain barrier and bloodâ€“tumour barrier in brain tumours and metastases. Nature Reviews Cancer, 2020, 20, 26-41.	12.8	908
29	Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors. American Journal of Pathology, 2002, 160, 985-1000.	1.9	885
30	Barriers to Drug Delivery in Solid Tumors. Scientific American, 1994, 271, 58-65.	1.0	884
31	Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics. Science, 2002, 296, 1883-1886.	6.0	869
32	Tumor Induction of VEGF Promoter Activity in Stromal Cells. Cell, 1998, 94, 715-725.	13.5	861
33	Transport of molecules across tumor vasculature. Cancer and Metastasis Reviews, 1987, 6, 559-593.	2.7	807
34	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17561-17566.	3.3	800
35	Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nature Medicine, 2003, 9, 796-800.	15.2	798
36	Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation. Cancer Cell, 2004, 6, 553-563.	7.7	789

#	Article	IF	Citations
37	Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvascular Research, 1989, 37, 77-104.	1.1	755
38	Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nature Communications, 2013, 4, 2516.	5.8	745
39	The Role of Mechanical Forces in Tumor Growth and Therapy. Annual Review of Biomedical Engineering, 2014, 16, 321-346.	5.7	742
40	Strategies for advancing cancer nanomedicine. Nature Materials, 2013, 12, 958-962.	13.3	717
41	Engineering vascularized tissue. Nature Biotechnology, 2005, 23, 821-823.	9.4	712
42	Solid stress inhibits the growth of multicellular tumor spheroids. Nature Biotechnology, 1997, 15, 778-783.	9.4	709
43	Cancer cells compress intratumour vessels. Nature, 2004, 427, 695-695.	13.7	706
44	Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nature Medicine, 2009, 15, 1219-1223.	15.2	692
45	Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15101-15108.	3.3	677
46	Herceptin acts as an anti-angiogenic cocktail. Nature, 2002, 416, 279-280.	13.7	664
47	Creation of long-lasting blood vessels. Nature, 2004, 428, 138-139.	13.7	644
48	Transport of Molecules, Particles, and Cells in Solid Tumors. Annual Review of Biomedical Engineering, 1999, 1, 241-263.	5.7	600
49	In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Medicine, 2001, 7, 864-868.	15.2	600
50	Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14608-14613.	3.3	595
51	Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvascular Research, 2007, 74, 72-84.	1.1	592
52	Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2909-2914.	3.3	583
53	Dissecting tumour pathophysiology using intravital microscopy. Nature Reviews Cancer, 2002, 2, 266-276.	12.8	576
54	Microvascular permeability of normal and neoplastic tissues. Microvascular Research, 1986, 31, 288-305.	1.1	564

#	Article	IF	Citations
55	Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model. Cancer Research, 2007, 67, 2729-2735.	0.4	556
56	Delivery of molecular and cellular medicine to solid tumors1PII of original article: S0169-409X(97)00027-6. The article was originally published in Advanced Drug Delivery Reviews 26 (1997) 71â€“90.1. Advanced Drug Delivery Reviews, 2001, 46, 149-168.	6.6	546
57	Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology, 2009, 6, 327-338.	12.5	541
58	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research, 2013, 73, 2943-2948.	0.4	535
59	Physiologically Based Pharmacokinetic Modeling: Principles and Applications. Journal of Pharmaceutical Sciences, 1983, 72, 1103-1127.	1.6	508
60	Mechanical compression drives cancer cells toward invasive phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 911-916.	3.3	507
61	Malignant cells facilitate lung metastasis by bringing their own soil. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21677-21682.	3.3	505
62	Diffusion of Macromolecules in Agarose Gels: Comparison of Linear and Globular Configurations. Biophysical Journal, 1999, 77, 542-552.	0.2	502
63	Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice. Journal of Investigative Dermatology, 1998, 111, 1-6.	0.3	498
64	Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry, 2007, 101, 937-949.	1.2	498
65	Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4465-4470.	3.3	498
66	Bone marrowâ€“derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood, 2008, 111, 4551-4558.	0.6	493
67	Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies. Annual Review of Chemical and Biomolecular Engineering, 2011, 2, 281-298.	3.3	491
68	Next-generation in vivo optical imaging with short-wave infrared quantum dots. Nature Biomedical Engineering, 2017, 1, .	11.6	490
69	Phase II Study of Cediranib, an Oral Panâ€“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2817-2823.	0.8	489
70	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	0.8	489
71	Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. Journal of Clinical Oncology, 2009, 27, 3020-3026.	0.8	487
72	Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies. Journal of the National Cancer Institute, 1990, 81, 570-576.	3.0	467

#	Article	IF	Citations
73	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of Clinical Oncology, 2009, 27, 3027-3035.	0.8	467
74	Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer and Metastasis Reviews, 1990, 9, 253-266.	2.7	461
75	Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium. Biophysical Journal, 2002, 83, 1650-1660.	0.2	457
76	HCC and angiogenesis: possible targets and future directions. Nature Reviews Clinical Oncology, 2011, 8, 292-301.	12.5	453
77	Spontaneous rupture of thin liquid films. Journal of the Chemical Society, Faraday Transactions 2, 1974, 70, 132.	1.1	452
78	Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2. New England Journal of Medicine, 2009, 361, 358-367.	13.9	446
79	The biology of brain metastasesâ€"translation to new therapies. Nature Reviews Clinical Oncology, 2011, 8, 344-356.	12.5	443
80	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	3.7	429
81	During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Medicine, 1996, 2, 992-997.	15.2	425
82	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nature Medicine, 2005, 11, 678-682.	15.2	419
83	Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients. Journal of Clinical Oncology, 2005, 23, 8136-8139.	0.8	410
84	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology, 2020, 17, 251-266.	12.5	408
85	Fluorescent Nanorods and Nanospheres for Realâ€Time In Vivo Probing of Nanoparticle Shapeâ€Dependent Tumor Penetration. Angewandte Chemie - International Edition, 2011, 50, 11417-11420.	7.2	399
86	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell, 2015, 28, 70-81.	7.7	389
87	Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends in Cancer, 2018, 4, 292-319.	3.8	389
88	Quantitative angiogenesis assays: Progress and problems. Nature Medicine, 1997, 3, 1203-1208.	15.2	385
89	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 2019, 21, 190-202.	4.6	384
90	CXCL12 (SDF1Î±)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?. Clinical Cancer Research, 2011, 17, 2074-2080.	3.2	377

#	Article	IF	Citations
91	Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models. Microcirculation, 2010, 17, 206-225.	1.0	376
92	Physical traits of cancer. Science, 2020, 370, .	6.0	371
93	A â€œVascular Normalization Indexâ€•as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research, 2009, 69, 5296-5300.	0.4	369
94	Micro-Environmental Mechanical Stress Controls Tumor Spheroid Size and Morphology by Suppressing Proliferation and Inducing Apoptosis in Cancer Cells. PLoS ONE, 2009, 4, e4632.	1.1	368
95	Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector. Cancer Research, 2006, 66, 2509-2513.	0.4	363
96	Combining two strategies to improve perfusion and drug delivery in solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18632-18637.	3.3	363
97	Origins of lymphatic and distant metastases in human colorectal cancer. Science, 2017, 357, 55-60.	6.0	358
98	CXCR4 inhibition in tumor microenvironment facilitates antiâ€programmed death receptorâ€1 immunotherapy in sorafenibâ€treated hepatocellular carcinoma in mice. Hepatology, 2015, 61, 1591-1602.	3.6	355
99	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	3.4	353
100	The next frontier of molecular medicine: Delivery of therapeutics. Nature Medicine, 1998, 4, 655-657.	15.2	348
101	The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature, 2004, 428, 328-332.	13.7	344
102	Coevolution of Solid Stress and Interstitial Fluid Pressure in Tumors During Progression: Implications for Vascular Collapse. Cancer Research, 2013, 73, 3833-3841.	0.4	342
103	Diffusion of Particles in the Extracellular Matrix: The Effect of Repulsive Electrostatic Interactions. Biophysical Journal, 2010, 99, 1342-1349.	0.2	340
104	Imaging Steps of Lymphatic Metastasis Reveals That Vascular Endothelial Growth Factor-C Increases Metastasis by Increasing Delivery of Cancer Cells to Lymph Nodes: Therapeutic Implications. Cancer Research, 2006, 66, 8065-8075.	0.4	323
105	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discovery, 2016, 6, 852-869.	7.7	318
106	Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood, 2008, 111, 1302-1305.	0.6	311
107	Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvascular Research, 1990, 40, 246-263.	1.1	309
108	Blocking Platelet-Derived Growth Factor-D/Platelet-Derived Growth Factor Receptor Î² Signaling Inhibits Human Renal Cell Carcinoma Progression in an Orthotopic Mouse Model. Cancer Research, 2005, 65, 5711-5719.	0.4	308

#	Article	IF	Citations
109	Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 855-860.	3.3	308
110	Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis. Circulation Research, 2003, 93, e88-97.	2.0	305
111	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19059-19064.	3.3	303
112	Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. Annual Review of Physiology, 2019, 81, 505-534.	5.6	303
113	Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clinical Cancer Research, 2002, 8, 1284-91.	3.2	303
114	A Nanoparticle Size Series for Inâ€...Vivo Fluorescence Imaging. Angewandte Chemie - International Edition, 2010, 49, 8649-8652.	7.2	289
115	TGF-Î² blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16618-16623.	3.3	287
116	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4476-4481.	3.3	287
117	Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptorâ€“Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. Journal of Clinical Oncology, 2009, 27, 2542-2552.	0.8	285
118	Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nature Biotechnology, 2007, 25, 317-318.	9.4	282
119	Solid stress and elastic energy as measures of tumour mechanopathology. Nature Biomedical Engineering, 2017, 1, .	11.6	280
120	Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Research, 2002, 62, 6831-6.	0.4	278
121	Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4558-4566.	3.3	274
122	Compact Biocompatible Quantum Dots via RAFT-Mediated Synthesis of Imidazole-Based Random Copolymer Ligand. Journal of the American Chemical Society, 2010, 132, 472-483.	6.6	271
123	BIM Expression in Treatment-NaÃ¯ve Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discovery, 2011, 1, 352-365.	7.7	268
124	Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006486-a006486.	2.9	266
125	A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nature Protocols, 2007, 2, 805-810.	5.5	265
126	Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Research, 2012, 72, 402-407.	0.4	264

#	Article	IF	Citations
127	Role of Tumor Vascular Architecture in Nutrient and Drug Delivery: An Invasion Percolation-Based Network Model. Microvascular Research, 1996, 51, 327-346.	1.1	258
128	Solid stress generated by spheroid growth estimated using a linear poroelasticity modelâˆ†. Microvascular Research, 2003, 66, 204-212.	1.1	254
129	Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. Cancer Research, 2010, 70, 5679-5685.	0.4	253
130	Delivery of molecular and cellular medicine to solid tumors. Advanced Drug Delivery Reviews, 2012, 64, 353-365.	6.6	251
131	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4470-4475.	3.3	251
132	Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nature Reviews Cancer, 2012, 12, 363-368.	12.8	250
133	YAP/TAZ Orchestrate VEGF Signaling during Developmental Angiogenesis. Developmental Cell, 2017, 42, 462-478.e7.	3.1	249
134	Acidic Extracellular pH Induces Vascular Endothelial Growth Factor (VEGF) in Human Glioblastoma Cells via ERK1/2 MAPK Signaling Pathway. Journal of Biological Chemistry, 2002, 277, 11368-11374.	1.6	247
135	Dual Programmed Death Receptorâ€1 and Vascular Endothelial Growth Factor Receptorâ€2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology, 2020, 71, 1247-1261.	3.6	247
136	Impaired lymphatic contraction associated with immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18784-18789.	3.3	246
137	Intussusceptive Microvascular Growth in a Human Colon Adenocarcinoma Xenograft: A Novel Mechanism of Tumor Angiogenesis. Microvascular Research, 1996, 51, 260-272.	1.1	244
138	Delivery of molecular and cellular medicine to solid tumors. Advanced Drug Delivery Reviews, 1997, 26, 71-90.	6.6	241
139	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Science Translational Medicine, 2017, 9, .	5.8	232
140	Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Seminars in Oncology, 2002, 29, 3-9.	0.8	232
141	Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncology, The, 2007, 8, 444-448.	5.1	230
142	p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science, 2010, 327, 593-596.	6.0	225
143	A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine, 2016, 8, 320ra4.	5.8	224
144	Magneto-fluorescent core-shell supernanoparticles. Nature Communications, 2014, 5, 5093.	5.8	223

#	Article	IF	Citations
145	Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends in Molecular Medicine, 2004, 10, 143-145.	3.5	219
146	A metastasis map of human cancer cell lines. Nature, 2020, 588, 331-336.	13.7	214
147	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. JAMA Oncology, 2021, 7, 113.	3.4	213
148	A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nature Medicine, 2005, 11, 998-1004.	15.2	212
149	Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nature Medicine, 2013, 19, 1178-1183.	15.2	212
150	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. Cell, 2013, 152, 1065-1076.	13.5	209
151	Design considerations for nanotherapeutics in oncology. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1893-1907.	1.7	208
152	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14325-14330.	3.3	206
153	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology, 2013, 15, 1079-1087.	0.6	205
154	Engineering and physical sciences in oncology: challenges and opportunities. Nature Reviews Cancer, 2017, 17, 659-675.	12.8	204
155	Transport of fluid and macromolecules in tumors. Microvascular Research, 1991, 41, 5-23.	1.1	203
156	CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1129-1138.	3.3	203
157	Cell-surface sensors for real-time probing of cellular environments. Nature Nanotechnology, 2011, 6, 524-531.	15.6	201
158	Scale-Invariant Behavior and Vascular Network Formation in Normal and Tumor Tissue. Physical Review Letters, 1995, 75, 2428-2431.	2.9	198
159	Microvascular Permeability of Albumin, Vascular Surface Area, and Vascular Volume Measured in Human Adenocarcinoma LS174T Using Dorsal Chamber in SCID Mice. Microvascular Research, 1993, 45, 269-289.	1.1	193
160	Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nature Methods, 2010, 7, 655-660.	9.0	192
161	Fractal Characteristics of Tumor Vascular Architecture During Tumor Growth and Regression. Microcirculation, 1997, 4, 395-402.	1.0	187
162	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of â€œReboundâ€•Revascularization as Mode of Escape. Cancer Research, 2011, 71, 19-28.	0.4	186

#	Article	IF	Citations
163	Role of nitric oxide in angiogenesis and microcirculation in tumors. , 1998, 17, 77-89.		184
164	Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Science Translational Medicine, 2016, 8, 360ra135.	5.8	184
165	Vasculogenic Mimicry: How Convincing, How Novel, and How Significant?. American Journal of Pathology, 2000, 156, 383-388.	1.9	180
166	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell, 2018, 33, 874-889.e7.	7.7	180
167	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology, 2014, 59, 1435-1447.	3.6	178
168	InAs(ZnCdS) Quantum Dots Optimized for Biological Imaging in the Near-Infrared. Journal of the American Chemical Society, 2010, 132, 470-471.	6.6	177
169	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nature Reviews Clinical Oncology, 2009, 6, 229-236.	12.5	175
170	Genetic evidence for a tumor suppressor role of HIF-2Î±. Cancer Cell, 2005, 8, 131-141.	7.7	174
171	Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2210-2219.	3.3	173
172	Response criteria for glioma. Nature Clinical Practice Oncology, 2008, 5, 634-644.	4.3	171
173	Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3725-3730.	3.3	169
174	Compatibility and the genesis of residual stress by volumetric growth. Journal of Mathematical Biology, 1996, 34, 889-914.	0.8	168
175	Delivery of Molecular and Cellular Medicine to Solid Tumors. Microcirculation, 1997, 4, 1-23.	1.0	167
176	Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1827-1832.	3.3	167
177	NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. Journal of Clinical Investigation, 2005, 115, 1816-1827.	3.9	167
178	Delivery of molecular and cellular medicine to solid tumors. Journal of Controlled Release, 1998, 53, 49-67.	4.8	166
179	Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nature Medicine, 2004, 10, 203-207.	15.2	163
180	Combining microenvironment normalization strategies to improve cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3728-3737.	3.3	163

#	Article	IF	Citations
181	Effect of Transvascular Fluid Exchange on Pressureâ€“Flow Relationship in Tumors: A Proposed Mechanism for Tumor Blood Flow Heterogeneity. Microvascular Research, 1996, 52, 27-46.	1.1	162
182	Formation of endothelial cell networks. Nature, 2000, 405, 139-141.	13.7	161
183	Perivascular nitric oxide gradients normalize tumor vasculature. Nature Medicine, 2008, 14, 255-257.	15.2	161
184	Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer, 2008, 8, 309-316.	12.8	160
185	Scaling rules for diffusive drug delivery in tumor and normal tissues. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1799-1803.	3.3	159
186	Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced bloodâ€“tumor barrier disruption. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8717-E8726.	3.3	159
187	Diffusion Anisotropy in Collagen Gels and Tumors: The Effect of Fiber Network Orientation. Biophysical Journal, 2010, 99, 3119-3128.	0.2	157
188	Water Channel (Aquaporin 1) Expression and Distribution in Mammary Carcinomas and Glioblastomas. Microvascular Research, 1999, 58, 89-98.	1.1	156
189	In vivo wide-area cellular imaging by side-view endomicroscopy. Nature Methods, 2010, 7, 303-305.	9.0	155
190	Compression of Pancreatic Tumor Blood Vessels by Hyaluronan Is Caused by Solid Stress and Not Interstitial Fluid Pressure. Cancer Cell, 2014, 26, 14-15.	7.7	155
191	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Science Translational Medicine, 2018, 10, .	5.8	153
192	Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1Î±, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. Cancer Research, 2009, 69, 7905-7910.	0.4	150
193	Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10674-10680.	3.3	150
194	Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?. Journal of Clinical Oncology, 2011, 29, 1-4.	0.8	148
195	Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer, 2021, 2, 414-428.	5.7	147
196	Lessons From Antiâ€“Vascular Endothelial Growth Factor and Antiâ€“Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma. Journal of Clinical Oncology, 2015, 33, 1197-1213.	0.8	145
197	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	7.7	145
198	Stability of symmetric and unsymmetric thin liquid films to short and long wavelength perturbations. Journal of Colloid and Interface Science, 1980, 78, 118-143.	5.0	141

#	Article	IF	Citations
199	Evidence for incorporation of bone marrowâ€“derived endothelial cells into perfused blood vessels in tumors. Blood, 2006, 107, 2774-2776.	0.6	141
200	Mechanics of interstitial-lymphatic fluid transport: theoretical foundation and experimental validation. Journal of Biomechanics, 1999, 32, 1297-1307.	0.9	140
201	Peritumor Lymphatics Induced by Vascular Endothelial Growth Factor-C Exhibit Abnormal Function. Cancer Research, 2004, 64, 4400-4404.	0.4	139
202	Imaging angiogenesis and the microenvironment. Apmis, 2008, 116, 695-715.	0.9	139
203	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research, 2013, 19, 6614-6623.	3.2	139
204	Matrix Metalloproteinases-1 and -8 Improve the Distribution and Efficacy of an Oncolytic Virus. Cancer Research, 2007, 67, 10664-10668.	0.4	137
205	Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12774-12779.	3.3	137
206	Membrane stability. BBA - Biomembranes, 1984, 779, 437-468.	7.9	136
207	Role of vascular normalization in benefit from metronomic chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1994-1999.	3.3	136
208	Transmural Coupling of Fluid Flow in Microcirculatory Network and Interstitium in Tumors. Microvascular Research, 1997, 53, 128-141.	1.1	132
209	Combined targeting of HER2 and VEGFR2 for effective treatment ofHER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3119-27.	3.3	131
210	Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers. Journal of Clinical Oncology, 2007, 25, 4033-4042.	0.8	130
211	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	130
212	Tumorâ€“host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor Î²1. Nature Medicine, 1999, 5, 1203-1208.	15.2	129
213	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 1048-1057.	3.2	129
214	What brings pericytes to tumor vessels?. Journal of Clinical Investigation, 2003, 112, 1134-1136.	3.9	128
215	A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. Journal of Applied Physiology, 2006, 101, 1162-1169.	1.2	127
216	Endothelial Nitric Oxide Synthase Mediates Lymphangiogenesis and Lymphatic Metastasis. Cancer Research, 2009, 69, 2801-2808.	0.4	127

#	Article	IF	Citations
217	Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nature Biomedical Engineering, 2019, 3, 230-245.	11.6	127
218	Vessels of Death or Life. Scientific American, 2001, 285, 38-45.	1.0	125
219	Angiopoietin-2 Interferes with Anti-VEGFR2â€"Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas. Clinical Cancer Research, 2010, 16, 3618-3627.	3.2	125
220	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine, 2007, 13, 223-230.	3.5	124
221	Vascular regulation of antitumor immunity. Science, 2019, 365, 544-545.	6.0	124
222	Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. Journal of Clinical Investigation, 2017, 127, 3039-3051.	3.9	124
223	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
224	A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood, 2003, 102, 2555-2561.	0.6	122
225	Using tumour phylogenetics to identify the roots of metastasis in humans. Nature Reviews Clinical Oncology, 2015, 12, 258-272.	12.5	122
226	Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy. Journal of Clinical Oncology, 2006, 24, 1449-1453.	0.8	121
227	In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts. Nature Methods, 2009, 6, 143-145.	9.0	120
228	Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clinical Cancer Research, 2002, 8, 1008-13.	3.2	120
229	Onset of Abnormal Blood and Lymphatic Vessel Function and Interstitial Hypertension in Early Stages of Carcinogenesis. Cancer Research, 2006, 66, 3360-3364.	0.4	119
230	Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood, 2011, 118, 4740-4749.	0.6	119
231	Emerging Strategies for Treating Brain Metastases from Breast Cancer. Cancer Cell, 2015, 27, 163-175.	7.7	119
232	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a027094.	2.9	119
233	Effect of Vascular Endothelial Growth Factor on Cultured Endothelial Cell Monolayer Transport Properties. Microvascular Research, 2000, 59, 265-277.	1.1	118
234	Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. Journal of Immunology, 2018, 200, 3000-3007.	0.4	118

#	Article	IF	Citations
235	Red Blood Cells Augment Leukocyte Rolling in a Virtual Blood Vessel. Biophysical Journal, 2002, 83, 1834-1841.	0.2	117
236	Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvascular Research, 1991, 41, 252-272.	1.1	116
237	Intratumoral Lymphatic Vessels: A Case of Mistaken Identity or Malfunction?. Journal of the National Cancer Institute, 2002, 94, 417-421.	3.0	116
238	mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discovery, 2014, 4, 42-52.	7.7	116
239	SnapShot: Tumor Angiogenesis. Cell, 2012, 149, 1408-1408.e1.	13.5	115
240	Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical Model. Annals of Biomedical Engineering, 2013, 41, 68-77.	1.3	115
241	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1547-1552.	3.3	115
242	Role of erythrocytes in leukocyte-endothelial interactions: mathematical model and experimental validation. Biophysical Journal, 1996, 71, 466-478.	0.2	113
243	Robust 3-D Modeling of Vasculature Imagery Using Superellipsoids. IEEE Transactions on Medical Imaging, 2007, 26, 223-237.	5.4	112
244	Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Research, 2002, 62, 2151-6.	0.4	111
245	Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS ONE, 2015, 10, e0141392.	1.1	110
246	Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1350-1355.	3.3	109
247	PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clinical Cancer Research, 2016, 22, 2993-3004.	3.2	109
248	Geometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma. Microcirculation, 1997, 4, 25-33.	1.0	107
249	Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation. Laboratory Investigation, 2001, 81, 1439-1451.	1.7	107
250	Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nature Cell Biology, 2014, 16, 931-941.	4.6	107
251	Angiogenesis as a Therapeutic Target in Malignant Gliomas. Oncologist, 2009, 14, 621-636.	1.9	106
252	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	106

#	Article	IF	Citations
253	Mosaic Tumor Vessels: Cellular Basis and Ultrastructure of Focal Regions Lacking Endothelial Cell Markers. Cancer Research, 2005, 65, 5740-5749.	0.4	104
254	Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 491-502.	3.3	104
255	Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors. Journal of the American Chemical Society, 2015, 137, 9832-9842.	6.6	104
256	Taming Vessels to Treat Cancer. Scientific American, 2008, 298, 56-63.	1.0	103
257	Return of Lymphatic Function After Flap Transfer for Acute Lymphedema. Annals of Surgery, 1999, 229, 421-427.	2.1	102
258	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. Journal of the National Cancer Institute, 2013, 105, 1188-1201.	3.0	101
259	A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 830-838.	0.4	101
260	Antiâ€“Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors. Cancer Research, 2010, 70, 3483-3493.	0.4	100
261	Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis, 2020, 23, 9-16.	3.7	100
262	PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment. PLoS ONE, 2009, 4, e5123.	1.1	99
263	Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Molecular Cancer Therapeutics, 2008, 7, 2272-2279.	1.9	98
264	Antiangiogenic therapy for cancer: current and emerging concepts. Oncology, 2005, 19, 7-16.	0.4	98
265	Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. Journal of the National Cancer Institute, 2015, 107, .	3.0	97
266	Targeting CXCR4-dependent immunosuppressive Ly6C ^{low} monocytes improves antiangiogenic therapy in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10455-10460.	3.3	97
267	Comparing machine learning algorithms for predicting ICU admission and mortality in COVID-19. Npj Digital Medicine, 2021, 4, 87.	5.7	97
268	Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nature Communications, 2021, 12, 2582.	5.8	96
269	Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer and Metastasis Reviews, 1996, 15, 195-204.	2.7	95
270	Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors. Cancer Research, 2008, 68, 3795-3802.	0.4	95

#	Article	IF	Citations
271	Analysis of cell flux in the parallel plate flow chamber: implications for cell capture studies. Biophysical Journal, 1994, 67, 889-895.	0.2	93
272	Decorin Inhibits Endothelial Migration and Tube-like Structure Formation: Role of Thrombospondin-1. Microvascular Research, 2001, 62, 26-42.	1.1	93
273	Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft. Circulation Research, 2001, 89, 732-739.	2.0	93
274	Cancer Cellâ€“Associated MT1-MMP Promotes Blood Vessel Invasion and Distant Metastasis in Triple-Negative Mammary Tumors. Cancer Research, 2011, 71, 4527-4538.	0.4	93
275	Dynamics of neovascularization in normal tissue. Microvascular Research, 1981, 21, 27-47.	1.1	92
276	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2â€“Associated Vestibular Schwannomas. Journal of Clinical Oncology, 2016, 34, 1669-1675.	0.8	92
277	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer, 2017, 123, 1979-1988.	2.0	92
278	Endothelial Nitric Oxide Synthase Regulates Microlymphatic Flow via Collecting Lymphatics. Circulation Research, 2004, 95, 204-209.	2.0	91
279	Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity. Cancer Cell, 2011, 19, 1-2.	7.7	91
280	New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics, 2017, 14, 321-332.	2.1	91
281	Extravascular transport in normal and tumor tissues. Critical Reviews in Oncology/Hematology, 1986, 5, 115-170.	2.0	89
282	Leaky vessels? Call Ang1!. Nature Medicine, 2000, 6, 131-132.	15.2	89
283	Benefits of Vascular Normalization Are Dose and Time Dependentâ€”Letter. Cancer Research, 2013, 73, 7144-7146.	0.4	89
284	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine, 2017, 9, .	5.8	89
285	Stability of stagnant viscous films on a solid surface. Journal of Colloid and Interface Science, 1976, 54, 108-116.	5.0	88
286	Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes. Biophysical Journal, 1995, 69, 2131-2138.	0.2	88
287	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-Oncology, 2010, 12, 466-72.	0.6	88
288	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87

#	Article	IF	Citations
289	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 302-307.	3.3	85
290	Combined Vascular Endothelial Growth Factorâ€"Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical Practice. Seminars in Oncology, 2006, 33, S35-S40.	0.8	84
291	Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer. Oncologist, 2010, 15, 577-583.	1.9	84
292	Continuous Noninvasive Monitoring of pH and Temperature in Rat Walker 256 Carcinoma During Normoglycemia and Hyperglycemia23. Journal of the National Cancer Institute, 1984, 73, 429-436.	3.0	83
293	Cancer, angiogenesis and fractals. Nature Medicine, 1998, 4, 984-984.	15.2	83
294	Blockade of VEGFR2 and Not VEGFR1 Can Limit Diet-Induced Fat Tissue Expansion: Role of Local versus Bone Marrow-Derived Endothelial Cells. PLoS ONE, 2009, 4, e4974.	1.1	83
295	Lymphotoxin-alpha contributes to lymphangiogenesis. Blood, 2010, 116, 2173-2182.	0.6	83
296	Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Journal of Neuro-Oncology, 2011, 103, 325-332.	1.4	82
297	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nature Protocols, 2015, 10, 1264-1274.	5.5	82
298	Spatial Charge Configuration Regulates Nanoparticle Transport and Binding Behavior Inâ€…Vivo. Angewandte Chemie - International Edition, 2013, 52, 1414-1419.	7.2	81
299	Conventional and High-Speed Intravital Multiphoton Laser Scanning Microscopy of Microvasculature, Lymphatics, and Leukocyteâ€"Endothelial Interactions. Molecular Imaging, 2002, 1, 9-15.	0.7	81
300	What brings pericytes to tumor vessels?. Journal of Clinical Investigation, 2003, 112, 1134-1136.	3.9	81
301	Pharmacologic Modification of Tumor Blood Flow and Interstitial Fluid Pressure in a Human Tumor Xenograft: Network Analysis and Mechanistic Interpretation. Microvascular Research, 1995, 50, 429-443.	1.1	80
302	Vascular Morphogenesis and Remodeling in a Model of Tissue Repair. Circulation Research, 2001, 89, 723-731.	2.0	79
303	Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases. PLoS ONE, 2009, 4, e8316.	1.1	79
304	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical Cancer Research, 2015, 21, 3610-3618.	3.2	79
305	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist, 2017, 22, 25-32.	1.9	79
306	Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior. Cell Research, 2018, 28, 221-248.	5.7	78

#	Article	IF	Citations
307	Mathematical Modeling of Herpes Simplex Virus Distribution in Solid Tumors: Implications for Cancer Gene Therapy. Clinical Cancer Research, 2009, 15, 2352-2360.	3.2	77
308	Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1081-1090.	0.4	77
309	Placenta Growth Factor Overexpression Inhibits Tumor Growth, Angiogenesis, and Metastasis by Depleting Vascular Endothelial Growth Factor Homodimers in Orthotopic Mouse Models. Cancer Research, 2006, 66, 3971-3977.	0.4	76
310	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 5959-5969.	3.2	75
311	Measurement of macromolecular diffusion coefficients in human tumors. Microvascular Research, 2004, 67, 231-236.	1.1	73
312	Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2662-2671.	3.3	73
313	Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends in Cancer, 2018, 4, 258-259.	3.8	72
314	Interlaboratory variation in oxygen tension measurement by Eppendorf â€œHistographâ€•and comparison with hypoxic marker. , 1997, 66, 30-38.		71
315	Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Seminars in Oncology, 2002, 29, 3-9.	0.8	71
316	Multiscale Measurements Distinguish Cellular and Interstitial Hindrances to Diffusion In Vivo. Biophysical Journal, 2009, 97, 330-336.	0.2	71
317	Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Research, 2002, 62, 4289-94.	0.4	71
318	Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Current Opinion in Neurology, 2008, 21, 728-735.	1.8	70
319	Quantifying solid stress and elastic energy from excised or in situ tumors. Nature Protocols, 2018, 13, 1091-1105.	5.5	70
320	Solid stress facilitates spheroid formation: potential involvement of hyaluronan. British Journal of Cancer, 2002, 86, 947-953.	2.9	69
321	Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors. Annals of Biomedical Engineering, 2015, 43, 2291-2300.	1.3	69
322	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 603-610.	1.4	69
323	VEGFR1-activity-independent metastasis formation. Nature, 2009, 461, E4-E4.	13.7	68
324	PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer. Clinical Cancer Research, 2011, 17, 3638-3648.	3.2	67

#	Article	IF	Citations
325	Wide-field three-photon excitation in biological samples. Light: Science and Applications, 2017, 6, e16255-e16255.	7.7	67
326	1995 Whitaker lecture: Delivery of molecules, particles, and cells to solid tumors. Annals of Biomedical Engineering, 1996, 24, 457-473.	1.3	66
327	Mice Lacking Eâ€Selection Show Normal Numbers of Rolling Leukocytes but Reduced Leukocyte Stable Arrest on Cytokineâ€Activated Microvascular Endothelium. Microcirculation, 1998, 5, 153-171.	1.0	66
328	Transgenic Mice for cGMP Imaging. Circulation Research, 2013, 113, 365-371.	2.0	66
329	Differential Dynamics of CD4+ and CD8+ T-Lymphocyte Proliferation and Activation in Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2000, 74, 8413-8424.	1.5	65
330	A New Target for Tumor Therapy. New England Journal of Medicine, 2009, 360, 2669-2671.	13.9	65
331	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research, 2013, 19, 1557-1566.	3.2	65
332	Obesity and Cancer: An Angiogenic and Inflammatory Link. Microcirculation, 2016, 23, 191-206.	1.0	64
333	Invited review: Response of tumours to hyperglycaemia: characterization, significance and role in hyperthermia. International Journal of Hyperthermia, 1988, 4, 223-250.	1.1	63
334	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 80-89.	3.2	62
335	Perfusion of Single Tumor Microvessels: Application to Vascular Permeability Measurement. Microcirculation, 1996, 3, 349-357.	1.0	61
336	Platelet-derived growth factor receptor-Î² in Gorham's disease. Nature Clinical Practice Oncology, 2006, 3, 693-697.	4.3	60
337	TGF-Î² Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models. Clinical Cancer Research, 2011, 17, 1415-1424.	3.2	60
338	A nanocrystal-based ratiometric pH sensor for natural pH ranges. Chemical Science, 2012, 3, 2980.	3.7	60
339	Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1033-1038.	3.3	60
340	Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell, 2003, 3, 515-516.	7.7	59
341	Metabolic Tumor Profiling with pH, Oxygen, and Glucose Chemosensors on a Quantum Dot Scaffold. Inorganic Chemistry, 2014, 53, 1900-1915.	1.9	59
342	A model for temporal heterogeneities of tumor blood flow. Microvascular Research, 2003, 65, 56-60.	1.1	58

#	Article	IF	Citations
343	Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?. Journal of the National Cancer Institute, 2012, 104, 899-905.	3.0	58
344	Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. Journal of the National Cancer Institute, 2016, 108, .	3.0	56
345	Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports, 2017, 7, 44123.	1.6	56
346	Lack of General Correlation between Interstitial Fluid Pressure and Oxygen Partial Pressure in Solid Tumors. Microvascular Research, 1995, 50, 175-182.	1.1	55
347	A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. Oncologist, 2010, 15, 845-851.	1.9	55
348	Vessel calibreâ€"a potential MRI biomarker of tumour response in clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 566-584.	12.5	55
349	Erythrocytes Enhance Lymphocyte Rolling and Arrest in Vivo. Microvascular Research, 2000, 59, 316-322.	1.1	52
350	Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nature Clinical Practice Oncology, 2007, 4, 316-321.	4.3	52
351	Differential Gene Expression of Primary Cultured Lymphatic and Blood Vascular Endothelial Cells. Neoplasia, 2007, 9, 1038-1045.	2.3	52
352	Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?. Journal of Clinical Oncology, 2010, 28, 183-185.	0.8	52
353	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.4	51
354	Antibody-Directed Effector Cell Therapy of Tumors: Analysis and Optimization Using a Physiologically Based Pharmacokinetic Model. Neoplasia, 2002, 4, 449-463.	2.3	50
355	Lack of Telopeptides in Fibrillar Collagen I Promotes the Invasion of a Metastatic Breast Tumor Cell Line. Cancer Research, 2005, 65, 5674-5682.	0.4	50
356	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1386-1392.	0.6	50
357	Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade. Cancer Immunology Research, 2021, 9, 765-778.	1.6	50
358	Differential Transplantability of Tumor-Associated Stromal Cells. Cancer Research, 2004, 64, 5920-5924.	0.4	49
359	A Mathematical Model of Murine Metabolic Regulation by Leptin: Energy Balance and Defense of a Stable Body Weight. Cell Metabolism, 2009, 9, 52-63.	7.2	49
360	Use of inhibitors of the reninâ€"angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 987-996.	1.6	49

#	Article	IF	Citations
361	Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer. PLoS ONE, 2012, 7, e38231.	1.1	48
362	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2020, 26, 206-212.	3.2	48
363	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	9.4	48
364	VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation. PLoS ONE, 2009, 4, e6525.	1.1	48
365	Automated tracing and change analysis of angiogenic vasculature from in vivo multiphoton confocal image time series. Microvascular Research, 2003, 66, 113-125.	1.1	47
366	Differential Gene Expression in Metastasizing Cells Shed from Kidney Tumors. Cancer Research, 2004, 64, 2469-2473.	0.4	47
367	Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer. Oncologist, 2012, 17, 212-219.	1.9	47
368	Merlin/NF2 Regulates Angiogenesis in Schwannomas through a Rac1/Semaphorin 3F-Dependent Mechanism. Neoplasia, 2012, 14, 84-94.	2.3	47
369	Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. Journal of Hematology and Oncology, 2013, 6, 51.	6.9	47
370	Mouse embryonic fibroblasts exhibit extensive developmental and phenotypic diversity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 122-127.	3.3	47
371	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Science Immunology, 2021, 6, .	5.6	47
372	In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model. Neuro-Oncology, 2010, 12, 341-350.	0.6	46
373	Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma. Cancer Research, 2011, 71, 3745-3752.	0.4	46
374	TEMPERATURE DISTRIBUTIONS IN NORMAL AND NEOPLASTIC TISSUES DURING NORMOTHERMIA AND HYPERTHERMIA. Annals of the New York Academy of Sciences, 1980, 335, 48-66.	1.8	45
375	Thinning and rupture of ring-shaped films. Journal of the Chemical Society, Faraday Transactions 2, 1980, 76, 250.	1.1	45
376	DEVELOPMENT: Lymphatics Make the Break. Science, 2003, 299, 209-210.	6.0	45
377	CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?. Immunity, 2017, 46, 773-775.	6.6	45
378	Microcirculatory flow changes during tissue growth. Microvascular Research, 1983, 25, 1-21.	1.1	44

#	Article	IF	Citations
379	A method for labeling cells for positron emission tomography (PET) studies. Journal of Immunological Methods, 1994, 175, 79-87.	0.6	44
380	Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14676-14681.	3.3	44
381	Convection and diffusion measurements using fluorescence recovery after photobleaching and video image analysis: In vitro calibration and assessment. Microvascular Research, 1990, 39, 77-93.	1.1	43
382	Paradoxical Effects of PDGF-BB Overexpression in Endothelial Cells on Engineered Blood Vessels In Vivo. American Journal of Pathology, 2009, 175, 294-302.	1.9	43
383	Video-rate resonant scanning multiphoton microscopy: An emerging technique for intravital imaging of the tumor microenvironment. Intravital, 2012, 1, 60-68.	2.0	43
384	Multistage Nanoparticles for Improved Delivery into Tumor Tissue. Methods in Enzymology, 2012, 508, 109-130.	0.4	43
385	ANGIOGENESIS IN THE huPBL-SCID MODEL OF HUMAN TRANSPLANT REJECTION1. Transplantation, 1999, 67, 1626-1631.	0.5	43
386	Non-Uniform Plasma Leakage Affects Local Hematocrit and Blood Flow: Implications for Inflammation and Tumor Perfusion. Annals of Biomedical Engineering, 2007, 35, 2121-2129.	1.3	42
387	Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Translational Oncology, 2016, 9, 431-437.	1.7	42
388	Prevention and Treatment of Lymphatic Metastasis by Antilymphangiogenic Therapy. Journal of the National Cancer Institute, 2002, 94, 785-787.	3.0	41
389	Lack of lymphatic vessel phenotype in LYVEâ€1/CD44 double knockout mice. Journal of Cellular Physiology, 2009, 219, 430-437.	2.0	41
390	Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. Journal of Neuro-Oncology, 2017, 134, 325-330.	1.4	41
391	In Vivo Imaging of Tumors. Cold Spring Harbor Protocols, 2010, 2010, pdb.prot5452-pdb.prot5452.	0.2	40
392	Reninâ€“Angiotensin System Inhibitors to Mitigate Cancer Treatmentâ€“Related Adverse Events. Clinical Cancer Research, 2018, 24, 3803-3812.	3.2	40
393	Dendritic cell paucity in mismatch repairâ€“proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	40
394	Kinetics of uptake, distribution, and excretion of zinc in rats. Annals of Biomedical Engineering, 1981, 9, 347-361.	1.3	39
395	Laser Speckle Rheology for evaluating the viscoelastic properties of hydrogel scaffolds. Scientific Reports, 2016, 6, 37949.	1.6	39
396	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS ONE, 2012, 7, e26331.	1.1	39

#	Article	IF	Citations
397	Interaction of Activated Natural Killer Cells with Normal and Tumor Vessels in Cranial Windows in Mice. Microvascular Research, 1995, 50, 35-44.	1.1	38
398	Evolution of Oxygen and Glucose Concentration Profiles in a Tissue-Mimetic Culture System of Embryonic Stem Cells. Annals of Biomedical Engineering, 2006, 34, 1247-1258.	1.3	38
399	Phase 2 and biomarker study of trebananib, an angiopoietinâ€blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer, 2018, 124, 1438-1448.	2.0	38
400	Down-Regulation of Placenta Growth Factor by Promoter Hypermethylation in Human Lung and Colon Carcinoma. Molecular Cancer Research, 2007, 5, 873-880.	1.5	37
401	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clinical Cancer Research, 2018, 24, 4643-4649.	3.2	37
402	Mapping Physical Tumor Microenvironment and Drug Delivery. Clinical Cancer Research, 2019, 25, 2024-2026.	3.2	37
403	The linear, hydrodynamic stability of an interfacially perturbed, transversely isotropic, thin, planar viscoelastic film. Journal of Colloid and Interface Science, 1982, 90, 233-262.	5.0	36
404	Transport of Macromolecules In Tumor Microcirculation. Biotechnology Progress, 1985, 1, 81-94.	1.3	36
405	Fluorescence Ratio Imaging Measurement of pH Gradients: Calibration and Application in Normal and Tumor Tissues. Microvascular Research, 1993, 46, 216-230.	1.1	36
406	Zooming in and out with quantum dots. Nature Biotechnology, 2004, 22, 959-960.	9.4	36
407	A homing system targets therapeutic T cells to brain cancer. Nature, 2018, 561, 331-337.	13.7	36
408	Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma. JAMA Oncology, 2019, 5, 1566.	3.4	36
409	T₁- and T₂*-Dominant Extravasation Correction in DSC-MRI: Part IIâ€”Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2054-2064.	2.4	35
410	Hypermutable DNA chronicles the evolution of human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1889-98.	3.3	35
411	Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1214.	3.3	34
412	Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. Nature Biomedical Engineering, 2020, 4, 801-813.	11.6	34
413	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut, 2022, 71, 185-193.	6.1	34
414	Dielectric Properties of Solid Tumors During Nonnothermia and Hyperthermia. IEEE Transactions on Biomedical Engineering, 1984, BME-31, 725-728.	2.5	33

#	Article	IF	Citations
415	Tissue-Isolated Human Tumor Xenografts in Athymic Nude Mice. Microvascular Research, 1994, 48, 389-402.	1.1	33
416	Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. Cancer Journal (Sudbury, Mass), 2009, 15, 263-268.	1.0	33
417	In silico dynamics of COVID-19 phenotypes for optimizing clinical management. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
418	Mice Lacking E-Selection Show Normal Numbers of Rolling Leukocytes but Reduced Leukocyte Stable Arrest on Cytokine-Activated Microvascular Endothelium. Microcirculation, 1998, 5, 153-171.	1.0	33
419	Oxygenation in tumors by modified hemoglobins. , 1996, 62, 109-114.		32
420	Effect of Local Anti-VEGF Antibody Treatment on Tumor Microvessel Permeability. Microvascular Research, 1999, 57, 357-362.	1.1	32
421	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2077-E2084.	3.3	32
422	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23684-23694.	3.3	32
423	Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comparative Medicine, 2008, 58, 253-63.	0.4	32
424	Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clinical Cancer Research, 2003, 9, 5508-13.	3.2	32
425	Clearing the smoke on nicotine and angiogenesis. Nature Medicine, 2001, 7, 775-777.	15.2	31
426	Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Antiâ€“Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors. Cancer Research, 2007, 67, 5076-5082.	0.4	31
427	Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Optics Letters, 2009, 34, 2066.	1.7	31
428	Premetastatic Lung â€œNicheâ€: Is Vascular Endothelial Growth Factor Receptor 1 Activation Required?. Cancer Research, 2010, 70, 5670-5673.	0.4	31
429	Tumor Physiology and Antibody Delivery1. Frontiers of Radiation Therapy and Oncology, 1989, 24, 32-46.	1.4	30
430	Pharmacokinetics of methotrexate in solid tumors. Journal of Pharmacokinetics and Pharmacodynamics, 1979, 7, 181-194.	0.6	29
431	Systemic Distribution and Tumor Localization of Adoptively Transferred Lymphocytes in Mice: Comparison with Physiologically Based Pharmacokinetic Model. Neoplasia, 2002, 4, 3-8.	2.3	29
432	A 2-D/3-D model-based method to quantify the complexity of microvasculature imaged by in vivo multiphoton microscopy. Microvascular Research, 2005, 70, 165-178.	1.1	29

#	Article	IF	Citations
433	Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value. Clinical Cancer Research, 2011, 17, 918-927.	3.2	29
434	Mathematical Model of Oxygen Transport in Tuberculosis Granulomas. Annals of Biomedical Engineering, 2016, 44, 863-872.	1.3	29
435	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1222-1225.	0.4	29
436	Kinetics of Placenta Growth Factor/Vascular Endothelial Growth Factor Synergy in Endothelial Hydraulic Conductivity and Proliferation. Microvascular Research, 2001, 61, 203-210.	1.1	28
437	An Indirect Way to Tame Cancer. Scientific American, 2014, 310, 46-53.	1.0	28
438	Compatibility and the genesis of residual stress by volumetric growth. Journal of Mathematical Biology, 1996, 34, 889-914.	0.8	28
439	Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model. PLoS Medicine, 2008, 5, e24.	3.9	27
440	Coronary Plaque Neovascularization and Hemorrhage. JACC: Cardiovascular Imaging, 2010, 3, 41-44.	2.3	27
441	Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model. PLoS ONE, 2011, 6, e17228.	1.1	27
442	Dehydro-Î±-lapachone, a plant product with antivascular activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11596-11601.	3.3	27
443	Pore and fiber-matrix models for diffusive transport in normal and neoplastic tissues. Microvascular Research, 1984, 28, 270-274.	1.1	26
444	Antiangiogenic agents for the treatment of glioblastoma. Expert Opinion on Investigational Drugs, 2007, 16, 1895-1908.	1.9	26
445	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research and Treatment, 2020, 179, 113-123.	1.1	26
446	Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Research, 2003, 63, 747-51.	0.4	26
447	Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. Journal of Controlled Release, 2022, 345, 190-199.	4.8	26
448	Mass Transport in Tumors: Characterization and Applications to Chemotherapy. Advances in Cancer Research, 1980, 33, 251-310.	1.9	25
449	The linear, hydrodynamic stability of an interfacially perturbed, transversely isotropic, thin, planar viscoelastic film. Journal of Colloid and Interface Science, 1982, 90, 263-276.	5.0	25
450	Vascular permeability and interstitial diffusion of macromolecules in the hamster cheek pouch: Effects of vasoactive drugs. Microvascular Research, 1987, 34, 336-348.	1.1	25

#	Article	IF	Citations
451	Transport Phenomena in Tumors. Advances in Chemical Engineering, 1994, 19, 129-200.	0.5	25
452	Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors. Advanced Drug Delivery Reviews, 2017, 119, 159-174.	6.6	25
453	Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 189-197.e3.	1.1	25
454	Enhanced metastasis formation by combined hyperthermia and hyperglycemia in rats bearing Walker 256 carcinosarcoma. Cancer Letters, 1983, 19, 317-323.	3.2	24
455	Î±PlGF: A New Kid on the Antiangiogenesis Block. Cell, 2007, 131, 443-445.	13.5	24
456	Vascular diseases await translation of blood vessels engineered from stem cells. Science Translational Medicine, 2015, 7, 309rv6.	5.8	24
457	In vivo compression and imaging in mouse brain to measure the effects of solid stress. Nature Protocols, 2020, 15, 2321-2340.	5.5	24
458	Spontaneous nonthymic tumors in SCID mice. Comparative Medicine, 2011, 61, 227-34.	0.4	24
459	Effect of Hemodilution and Resuscitation on Tumor Interstitial Fluid Pressure, Blood Flow, and Oxygenation. Microvascular Research, 1994, 48, 1-12.	1.1	23
460	Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2731-2734.	1.0	23
461	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. Npj Precision Oncology, 2021, 5, 62.	2.3	23
462	N,N-Dichloroaminosulfonic acids as novel topical antimicrobial agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 196-198.	1.0	22
463	MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. Journal of Neuro-Oncology, 2018, 136, 63-71.	1.4	22
464	Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2022, 114, 1301-1305.	3.0	22
465	In vitro measurement and screening of monoclonal antibody affinity using fluoroscence photobleaching. Journal of Immunological Methods, 1992, 155, 1-17.	0.6	21
466	Lateral View Flow System for Studies of Cell Adhesion and Deformation under Flow Conditions. BioTechniques, 2001, 30, 388-394.	0.8	21
467	Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent MÃ¼llerian Carcinoma. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2011, 4, 26-33.	0.2	21
468	A transient parabiosis skin transplantation model in mice. Nature Protocols, 2012, 7, 763-770.	5.5	21

#	Article	IF	Citations
469	Correlative intravital imaging of cGMP signals and vasodilation in mice. Frontiers in Physiology, 2014, 5, 394.	1.3	21
470	A cerebellar window for intravital imaging of normal and disease states in mice. Nature Protocols, 2017, 12, 2251-2262.	5.5	21
471	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Science Translational Medicine, 2021, 13, .	5.8	21
472	Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. American Journal of Cancer Research, 2011, 1, 144-54.	1.4	21
473	Reninâ€“angiotensinâ€“aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. European Journal of Cancer, 2022, 163, 108-118.	1.3	21
474	Small Blood Vessel Engineering. Methods in Molecular Medicine, 2008, 140, 183-195.	0.8	20
475	Kinetics of interleukin-2 induced changes in rigidity of human natural killer cells. Cell Biophysics, 1992, 20, 161-176.	0.4	19
476	Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiation Oncology, 2021, 16, 48.	1.2	19
477	Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers. Oncotarget, 2017, 8, 108292-108302.	0.8	19
478	Reduction of rigidity in human activated natural killer cells by thioglycollate treatment. Journal of Immunological Methods, 1994, 175, 69-77.	0.6	18
479	Mast Cells Contribute to Radiation-Induced Vascular Hyperpermeability. Radiation Research, 2016, 185, 182-189.	0.7	18
480	A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nature Protocols, 2019, 14, 541-555.	5.5	18
481	The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy. Cancer Cell, 2022, 40, 701-702.	7.7	18
482	Instability and rupture of thin liquid films. , 1979, , 140-167.		17
483	Vascular permeability and interstitial diffusion in superfused tissues: A two-dimensional model. Microvascular Research, 1988, 36, 108-115.	1.1	17
484	Studying primary tumorâ€“associated fibroblast involvement in cancer metastasis in mice. Nature Protocols, 2012, 7, 756-762.	5.5	17
485	Molecular Regulation of Microlymphatic Formation and Function: Role of Nitric Oxide. Trends in Cardiovascular Medicine, 2005, 15, 169-173.	2.3	16
486	VEGFR3: A New Target for Antiangiogenesis Therapy?. Developmental Cell, 2008, 15, 178-179.	3.1	16

#	Article	IF	Citations
487	Stieglitz rearrangement of N,N-dichloro-Î²,Î²-disubstituted taurines under mild aqueous conditions. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1110-1114.	1.0	16
488	Low Incidence of Pseudoprogression by Imaging in Newly Diagnosed Glioblastoma Patients Treated With Cediranib in Combination With Chemoradiation. Oncologist, 2014, 19, 75-81.	1.9	16
489	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. Npj Precision Oncology, 2017, 1, .	2.3	16
490	Targeted therapy in rectal cancer. Oncology, 2007, 21, 1055-65; discussion 1065, 1070, 1075 passim.	0.4	16
491	ANALYSIS OF DIFFUSIVE AND CONVECTIVE RECOVERY OF FLUORESCENCE AFTER PHOTOBLEACHINGâ€"EFFECT OF UNIFORM FLOW FIELD. Chemical Engineering Communications, 1987, 55, 235-249.	1.5	15
492	Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?. Journal of the National Cancer Institute, 2013, 105, 762-765.	3.0	15
493	Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?. Cancer Research, 2019, 79, 2104-2106.	0.4	15
494	Inducible Nitric Oxide Synthase and CD11b⁺Gr1⁺ Cells Impair Lymphatic Contraction of Tumor-Draining Lymphatic Vessels. Lymphatic Research and Biology, 2019, 17, 294-300.	0.5	15
495	Mice Lacking E-Selectin Show Normal Numbers of Rolling Leukocytes but Reduced Leukocyte Stable Arrest on Cytokine-Activated Microvascular Endothelium. Microcirculation, 0, 5, 153-171.	1.0	15
496	Pharmacokinetics of methotrexate in leukemia cells: Effect of dose and mode of injection. Journal of Pharmacokinetics and Pharmacodynamics, 1978, 6, 487-503.	0.6	14
497	Monitoring transport in the rabbit ear chamber. Microvascular Research, 1982, 24, 204-209.	1.1	14
498	Two-compartment model for plasma pharmacokinetics in individual blood vessels. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 451-461.	0.6	14
499	Anti-VEGF treatment improves neurological function in tumors of the nervous system. Experimental Neurology, 2018, 299, 326-333.	2.0	14
500	FOLFOX plus zivâ€aflibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. Cancer, 2019, 125, 2213-2221.	2.0	14
501	Effects of cediranib (VEGF signaling inhibitor) on edema in newly diagnosed glioblastoma patients during initial chemoradiation.. Journal of Clinical Oncology, 2012, 30, 2012-2012.	0.8	14
502	Conventional and High-Speed Intravital Multiphoton Laser Scanning Microscopy of Microvasculature, Lymphatics, and Leukocyte-Endothelial Interactions. Molecular Imaging, 2002, 1, 153535002002000.	0.7	13
503	Anti-vascular endothelial growth factor therapy for malignant glioma. Current Neurology and Neuroscience Reports, 2009, 9, 254-262.	2.0	13
504	Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse. Comparative Medicine, 2005, 55, 236-43.	0.4	13

#	Article	IF	Citations
505	Temperature distributions and thermal response in humans. I. Simulations of various modes of whole-body hyperthermia in normal subjects. Medical Physics, 1982, 9, 506-513.	1.6	12
506	Novel N-chloroheterocyclic antimicrobials. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3029-3033.	1.0	12
507	Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. Npj Breast Cancer, 2019, 5, 4.	2.3	12
508	Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. Journal of Clinical Investigation, 2005, 115, 596-598.	3.9	12
509	Reply to 'Recognition of tumor blood vessel normalization as a new antiangiogenic concept'. Nature Medicine, 2004, 10, 329-330.	15.2	11
510	An isolated tumor perfusion model in mice. Nature Protocols, 2012, 7, 749-755.	5.5	11
511	Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment. Cancer Journal (Sudbury, Mass), 2015, 21, 307-313.	1.0	11
512	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Scientific Reports, 2018, 8, 17062.	1.6	11
513	Transvascular and Interstitial Transport in Tumors. Advances in Experimental Medicine and Biology, 1988, 242, 215-220.	0.8	11
514	Is vasculogenesis crucial for the regrowth of irradiated tumours?. Nature Reviews Cancer, 2011, 11, 532-532.	12.8	11
515	Effects of Needle Insertion in Tumors on Interstitial Fluid Pressure. Microvascular Research, 1997, 54, 174-177.	1.1	10
516	Changes in Vascularization of Human Breast Cancer Xenografts Responding to Antiestrogen Therapy. Neoplasia, 1999, 1, 518-525.	2.3	10
517	A protocol for a lung neovascularization model in rodents. Nature Protocols, 2008, 3, 378-387.	5.5	10
518	Is vasculogenesis crucial for the regrowth of irradiated tumours?. Nature Reviews Cancer, 2011, 11, 532-532.	12.8	10
519	Measuring Angiogenesis and Hemodynamics in Mice. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot073916.	0.2	10
520	Increasing the penetration depth of temporal focusing multiphoton microscopy for neurobiological applications. Journal Physics D: Applied Physics, 2019, 52, 264001.	1.3	10
521	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 540-546.	0.9	10
522	Analysis of Heat Transfer and Temperature Distributions in Tissues during Local and Whole-Body Hyperthermia. , 1985, , 3-54.		10

#	Article	IF	Citations
523	Temperature distributions in normal and neoplastic tissues during hyperthermia: lumped parameter analysis. Journal of Thermal Biology, 1979, 4, 157-164.	1.1	9
524	Heating or freezing bone: Effects on angiogenesis induction and growth potential in mice. Acta Orthopaedica, 1996, 67, 383-388.	1.4	9
525	A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nature Protocols, 2008, 3, 388-397.	5.5	9
526	Judah Folkman. Journal of Clinical Investigation, 2008, 118, 823-823.	3.9	9
527	A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 1026-1026.	0.8	9
528	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology, 2018, 36, 4116-4116.	0.8	9
529	Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling. EBioMedicine, 2022, 75, 103809.	2.7	9
530	Quantitative analysis of angiogenesis and growth of bone: effect of indomethacin exposure in a combined in vitro-in vivo approach. Research in Experimental Medicine, 1995, 195, 275-288.	0.7	8
531	Visualizing anti-tumor immune responses in vivo. DMM Disease Models and Mechanisms, 2009, 2, 107-110.	1.2	8
532	Novel 3-chlorooxazolidin-2-ones as antimicrobial agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3025-3028.	1.0	8
533	Seeds and Soil: Unraveling the Role of Local Tumor Stroma in Distant Metastasis. Journal of the National Cancer Institute, 2014, 106, dju187-dju187.	3.0	8
534	NAD ⁺ -mediated rescue of prenatal forebrain angiogenesis restores postnatal behavior. Science Advances, 2020, 6, .	4.7	8
535	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.4	8
536	Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function, and Drug Delivery in Tumors. , 0, , 647-671.		8
537	Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Therapeutic Effects in Tumors. , 2011, , 641-679.		7
538	Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Cancer Research, 2008, 68, LB-247-LB-247.	0.4	7
539	Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2009-2009.	0.8	7
540	Microvascular network architecture in a mammary carcinoma. Exs, 1992, 61, 74-80.	1.4	7

#	Article	IF	Citations
541	Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clinical Genitourinary Cancer, 2022, 20, 301-306.	0.9	7
542	Measuring Vascular Permeability in Mice. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot074344-pdb.prot074344.	0.2	6
543	From the Guest Editors. Cancer Journal (Sudbury, Mass), 2015, 21, 235-236.	1.0	6
544	Abstract 3975: Matrix-depleting anti-hypertensives decompress tumor blood vessels and improve perfusion in patients with glioblastomas receiving anti-angiogenic therapy. , 2016, , .		6
545	Preliminary model for streptozocin metabolism in mice. Journal of Pharmaceutical Sciences, 1980, 69, 691-694.	1.6	5
546	ANALYSIS OF TRANSIENT TEMPERATURE DISTRIBUTIONS IN A PERFUSED MEDIUM DUE TO A SPHERICAL HEAT SOURCE WITH APPLICATION TO HEAT TRANSFER IN TUMORS: HOMOGENEOUS AND INFINITE MEDIUM. Chemical Engineering Communications, 1980, 4, 95-118.	1.5	5
547	Structure stability/activity relationships of sulfone stabilized N,N-dichloroamines. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3682-3685.	1.0	5
548	Closing the gap: astrocytes and brain metastasis. Cell Research, 2016, 26, 973-974.	5.7	5
549	A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research, 2022, 28, 3950-3957.	3.2	5
550	Intratumour temperature distributions during hyperthermia. Journal of Thermal Biology, 1980, 5, 127-130.	1.1	4
551	Thermal interactions between normal and neoplastic tissues in the rat, rabbit, swine, and dog during hyperthermia. Medical Physics, 1980, 7, 529-536.	1.6	4
552	In Vitro and In Vivo Quantification of Adhesion Between Leukocytes and Vascular Endothelium. , 1999, 18, 553-576.		4
553	A Potential Murine Model for Flap-Related Investigations. Plastic and Reconstructive Surgery, 2001, 107, 1504-1508.	0.7	4
554	Notch Leads Lymphatics and Links Them to Blood Vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1682-1683.	1.1	4
555	Lymphangiography of the Mouse Ear. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot072116.	0.2	4
556	Sulfonyl-polyol N,N-dichloroamines with rapid, broad-spectrum antimicrobial activity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5650-5653.	1.0	4
557	Improving treatment of liver metastases by targeting nonangiogenic mechanisms. Nature Medicine, 2016, 22, 1209-1210.	15.2	4
558	Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?. Breast Cancer Research and Treatment, 2017, 165, 467-468.	1.1	4

#	Article	IF	Citations
559	Normalizing the Tumor Microenvironment for Radiosensitization. Cancer Drug Discovery and Development, 2020, , 301-338.	0.2	4
560	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Translational Cancer Research, 2018, 7, S16-S20.	0.4	4
561	Gabrb3 endothelial cell-specific knockout mice display abnormal blood flow, hypertension, and behavioral dysfunction. Scientific Reports, 2022, 12, 4922.	1.6	4
562	Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. Clinical Cancer Research, 2022, 28, 3076-3090.	3.2	4
563	Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site. Oncology Reports, 2004, 11, 803.	1.2	3
564	Reply to S.J. Faivre et al. Journal of Clinical Oncology, 2009, 27, e251-e252.	0.8	3
565	Measuring Interstitial Diffusion, Convection, and Binding Parameters in Mouse Tumors. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot075721.	0.2	3
566	A Physical View of Cancer. Trends in Cancer, 2018, 4, 257.	3.8	3
567	Tumor Microenvironment. , 2020, , 108-126.e7.		3
568	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 273-281.		3
569	Extravasation and Interstitial Transport in Tumors. Pharmaceutical Biotechnology, 1993, , 441-465.	0.3	3
570	Effects of Hyperthermia and Hyperglycemia on the Metastases Formation and on Survival of Rat Bearing W256 Carcinosarcoma. Advances in Experimental Medicine and Biology, 1982, 157, 23-42.	0.8	3
571	Vascular and Interstitial Biology of Tumors. , 2014, , 108-126.e5.		3
572	Abstract 548: Multistage nanoparticle delivery system for deep penetration into solid tumor. Cancer Research, 2011, 71, 548-548.	0.4	3
573	Impact of adjuvant anti-VEGF therapy on treatment-related pseudoprogression in patients with newly diagnosed glioblastoma receiving chemoradiation with or without anti-VEGF therapy.. Journal of Clinical Oncology, 2012, 30, 2025-2025.	0.8	3
574	Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1093-1093.	0.8	3
575	Correspondence re: S. Maula et al., intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinoma of the head and neck. Cancer Res., 63: 1920-1926, 2003. Cancer Research, 2003, 63, 8555-6; author reply 8558.	0.4	3
576	In Vivo Pharmacokinetics of Triazinate in L-1210 and W-256 Cells. Journal of Pharmaceutical Sciences, 1982, 71, 1102-1105.	1.6	2

#	Article	IF	Citations
577	Measurement of physiological parameters in tumors in vivo using MPLSM. , 2001, , .		2
578	Anti-VEGFR-3 Therapy and Lymph Node Metastasis. Cancer Research, 2007, 67, 5055-5055.	0.4	2
579	Pancreatic Tumor Preparation in Mice. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot072363.	0.2	2
580	Rabbit Ear Chambers. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot070045-pdb.prot070045.	0.2	2
581	Corneal Pocket Assay in Rabbits: Figure 1.. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot070052.	0.2	2
582	Lessons From 30 Years of Teaching About the Microenvironment of Tumors. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	2
583	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 429-429.	0.8	2
584	Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer. Clinical Cancer Research, 2021, 27, 2706-2711.	3.2	2
585	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 261-276.		2
586	Vascular and Interstitial Biology of Tumors. , 2008, , 105-124.		2
587	Abstract LB-344: Vascular normalization as an emerging strategy to enhance cancer immunotherapy.. Cancer Research, 2013, 73, LB-344-LB-344.	0.4	2
588	Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models. , 2015, , .		2
589	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 2031-2031.	0.8	2
590	Abstract LB-297: Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.. , 2013, , .		2
591	A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1080-1080.	0.8	2
592	Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. , 2016, , .		2
593	Hypoxia-induced DNA hypermethylation: another reason to normalize tumor vessels. Translational Cancer Research, 2016, 5, S1358-S1362.	0.4	2
594	Abstract B12: Adding angiotensin-system inhibitors to anti-angiogenic therapy reduces vasogenic edema in newly diagnosed glioblastomas but not in recurrent disease. , 2017, , .		2

#	Article	IF	Citations
595	Kendrick Mass Defect Variation to Decipher Isotopic Labeling in Brain Metastases Studied by Mass Spectrometry Imaging. Analytical Chemistry, 2021, 93, 16314-16319.	3.2	2
596	Effect of transmembrane potential on the deformability of RBC's suspended in carbohydrate-saline solutions. Journal of Colloid and Interface Science, 1986, 114, 273-276.	5.0	1
597	Improved physiological parameters in murine & human tumors by nicotinamide. International Journal of Radiation Oncology Biology Physics, 1993, 27, 305.	0.4	1
598	The orthotopic microenvironment promotes tumor growth and VEGF121 expression in human pancreatic adenocarcinoma. Gastroenterology, 2000, 118, A1415.	0.6	1
599	Reply to â€œPET concerns in bevacizumab treatmentâ€. Nature Medicine, 2004, 10, 561-561.	15.2	1
600	Novel function of RANKL: eNOS activator. Blood, 2007, 109, 1339-1340.	0.6	1
601	Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer. Current Colorectal Cancer Reports, 2007, 3, 94-98.	1.0	1
602	Angiogenesis in Development, Disease, and Regeneration. , 2009, , 1-41.		1
603	Lymphangiography of the Mouse Tail. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot072108.	0.2	1
604	Design rules for cancer nanomedicines. , 2012, , .		1
605	Lung Window Preparation in Mice. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot072678.	0.2	1
606	Measuring Leukocyte-Endothelial Interactions in Mice. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot075085.	0.2	1
607	Measuring Interstitial pH and pO₂ in Mouse Tumors. Cold Spring Harbor Protocols, 2013, 2013, pdb.prot075713.	0.2	1
608	Combined Angiotensin Receptor Blocker Losartan and the CXCR4 Inhibitor AMD3100 Increases the Efficacy of Radiotherapy in a Metastatic Osteosarcoma Mouse Model. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	1
609	Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy. Circulation Research, 2020, 127, 724-726.	2.0	1
610	Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2021, 39, 453-453.	0.8	1
611	Implications of a granulocyteâ€high glioblastoma microenvironment in immune suppression and therapy resistance â€. Journal of Pathology, 2021, 254, 105-108.	2.1	1
612	Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer. , 2008, , .		1

#	Article	IF	Citations
613	Abstract LB-203: Obesity promotes resistance to anti-VEGF therapy in breast cancer via pro-inflammatory and angiogenic pathways. , 2015, , .		1
614	Abstract IA4: Normalizing the tumor microenvironment to enhance therapeutic outcome. , 2011, , .		1
615	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2010-2010.	0.8	1
616	Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).. Journal of Clinical Oncology, 2012, 30, 4112-4112.	0.8	1
617	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 2543-2543.	0.8	1
618	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2015, 33, TPS2080-TPS2080.	0.8	1
619	Compressionâ€induced cell distension stimulates coordinated migration of mammary carcinoma cells. FASEB Journal, 2010, 24, 39.3.	0.2	1
620	Abstract C1: Functional normalization of the breast cancer vasculature through activation of Tie2 using a vascular-endothelial protein tyrosine phosphatase inhibitor.. Molecular Cancer Therapeutics, 2013, 12, C1-C1.	1.9	1
621	Angiotensin system inhibitors during induction chemotherapy for esophageal adenocarcinoma: Analysis of survival.. Journal of Clinical Oncology, 2018, 36, e16066-e16066.	0.8	1
622	A semi-empirical model for cell kill kinetics during hyperthermia. Journal of Thermal Biology, 1979, 4, 257-258.	1.1	0
623	Automated in vivo change analysis of tumor vasculature from two-photon confocal image time series. , 2003, , .		0
624	Robust Parametric Modeling for Improved Segmentation of Complex Tumor Microvasculature from Multiphoton Microscopy Data. Microscopy and Microanalysis, 2004, 10, 176-177.	0.2	0
625	Tumor Imaging. , 0, , 277-309.		0
626	Optical Microscopy in Small Animal Research. , 0, , 183-190.		0
627	Guest Editorial: Optical Methods in Vascular Biology and Medicine. Journal of Biomedical Optics, 2010, 15, 011001.	1.4	0
628	Residual Stresses in Solid Tumors: Implications to Tumor Growth and Drug Delivery. , 2012, , .		0
629	Skeletal Muscle Myopathy Mutations at the Actin-Tropomyosin Interface that Cause Gain Or Loss of Function. Biophysical Journal, 2012, 102, 231a.	0.2	0
630	Letter to the editor regarding recent article by Wu et al. [J. Theor. Biol. 355 (2014) pp. 194â€“207]. Journal of Theoretical Biology, 2014, 363, 453.	0.8	0

#	Article	IF	Citations
631	AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA. Neuro-Oncology, 2014, 16, v16-v17.	0.6	0
632	ANGI-04Olig2 REGULATES Wnt7b EXPRESSION AND VASCULATURE CHARACTERISTICS IN GLIOMA. Neuro-Oncology, 2015, 17, v41.4-v41.	0.6	0
633	Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3454-E3454.	3.3	0
634	IMST-40. REPROGRAMMING OF THE TUMOR IMMUNE MICROENVIRONMENT BY AN ANG-2/VEGF BISPECIFIC ANTIBODY DELAYS TUMOR GROWTH AND PROLONGS SURVIVAL IN PRECLINICAL GBM MODELS. Neuro-Oncology, 2016, 18, vi95-vi95.	0.6	0
635	Laser speckle micro rheology for micro-mechanical mapping of bio-materials (Conference) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50		0
636	Antiangiogenic Therapy for Malignant Gliomas. , 2017, , 163-175.		0
637	Notice of Removal: Evaluation of anticancer agent transport in brain tumors after focused ultrasound-induced blood-brain/blood-tumor barrier disruption. , 2017, , .		0
638	CADD-32. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN TUMORS WITH FOCUSED ULTRASOUND-INDUCED TRANSIENT BLOOD-TUMOR BARRIER DISRUPTION. Neuro-Oncology, 2018, 20, vi281-vi281.	0.6	0
639	BSCI-10. NEUROLOGICAL DYSFUNCTION CAUSED BY BRAIN TUMOR-GENERATED SOLID STRESS IS REVERSED BY LITHIUM. Neuro-Oncology Advances, 2019, 1, i2-i3.	0.4	0
640	BSCI-09. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN METASTASES WITH FOCUSED ULTRASOUND-INDUCED BLOOD-TUMOR BARRIER DISRUPTION. Neuro-Oncology Advances, 2019, 1, i2-i2.	0.4	0
641	IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA. Neuro-Oncology, 2019, 21, vi119-vi120.	0.6	0
642	DDRE-22. TARGETING SERINE SYNTHESIS IN BRAIN METASTASIS. Neuro-Oncology Advances, 2021, 3, i11-i11.	0.4	0
643	A Novel Culture System of Human ES Cells for High Efficient Hematopoietic and Endothelial Differentiation.. Blood, 2005, 106, 3616-3616.	0.6	0
644	Phenotypic and functional characterization of proangiogenic monocytes. FASEB Journal, 2008, 22, 238.7.	0.2	0
645	In Vivo Fluorescence Cellular Imaging by Side-view Endomicroscopy. , 2010, , .		0
646	Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, , .		0
647	Wrapping and Tapping Anastomosis between Engrafted Endothelial Networks and Host Vasculature. FASEB Journal, 2010, 24, 235.5.	0.2	0
648	Abstract LB-76: A study of neoadjuvant bevacizumab with standard chemoradiation versus chemoradiation alone in locally advanced rectal cancer. , 2010, , .		0

#	Article	IF	Citations
649	Abstract 1579: TGF-Î² blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma model. , 2011, , .		0
650	Abstract LB-288: Restoration of peri-vascular nitric oxide gradient radio-sensitizes murine breast cancers via vascular normalization.. , 2011, , .		0
651	Abstract 715: TGF-beta blockade improves the distribution and efficacy of chemotherapeutic agents in breast carcinoma. , 2011, , .		0
652	Side-View Endomicroscopy for High-Resolution In Vivo Imaging of the Gastrointestinal Tract. , 2012, , 333-348.		0
653	Abstract PL02-01: Normalizing the tumor microenvironment to enhance therapeutic outcome. , 2012, , .		0
654	Abstract A67: Reconditioning the tumor immune microenvironment for a breast cancer vaccine therapy.. , 2013, , .		0
655	Abstract LB-339: Increase in tumor-associated macrophages (TAMs) after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma (GBM) patients.. , 2013, , .		0
656	Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). , 2013, , .		0
657	Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo. , 2013, , .		0
658	Abstract 3925: Optical coherence tomography imaging in cancer research.. , 2013, , .		0
659	Abstract LB-348: Evolution of physical forces in the tumor microenvironment and implications for therapeutic resistance.. , 2013, , .		0
660	Normalizing tumor vasculature and microenvironment: Insights from in vivo microscopy. FASEB Journal, 2013, 27, 18.1.	0.2	0
661	Neuropilin-1 (Nrp-1) as a prognostic biomarker and potential drug target for pediatric medulloblastoma.. Journal of Clinical Oncology, 2013, 31, 2056-2056.	0.8	0
662	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0
663	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	0.8	0
664	Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 1065-1065.	0.8	0
665	Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.. , 2013, , .		0
666	INTERSTITIAL HYPERTENSION IN EXPERIMENTAL AND HUMAN TUMORS: ETIOLOGY AND THERAPEUTIC IMPLICATIONS. , 1992, , 768-771.		0

#	Article	IF	Citations
667	Tumor Microcirculation: Role in Drug and Nutrient Delivery. , 1997, , 46-70.		0
668	Tumor Microcirculation. , 1998, , 319-345.		0
669	Abstract LB-267: Role of VEGFR-1 signaling in obesity-induced tumor progression. , 2015, , .		0
670	Abstract B79: CXCR4 inhibition facilitates anti-PD-1 immunotherapy by reprogramming the tumor microenvironment during sorafenib treatment in hepatocellular carcinoma. , 2015, , .		0
671	Value of correlative biomarkers in understanding tumor biology. Translational Cancer Research, 2016, 5, 211-212.	0.4	0
672	Abstract B03: Formation of lymph node metastases is not angiogenesis dependent. , 2016, , .		0
673	Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice. , 2016, , .		0
674	Abstract 4195: Targeting the immune microenvironment to improve colorectal cancer anti-angiogenic therapy. , 2016, , .		0
675	Abstract PR06: VEGF-targeted therapy induces extracellular matrix remodeling and increases mechanical barriers to therapy in colorectal cancer liver metastases. , 2017, , .		0
676	Abstract B59: Mathematical Model of Oxygen Transport in Tuberculosis Granulomas. , 2017, , .		0
677	Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. , 2017, , .		0
678	A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2018, 36, 1026-1026.	0.8	0
679	Abstract SY38-03: Microenvironment dictates differential responseof primary tumor versus metastases. , 2018, , .		0
680	Abstract LB-057: Hypoxia regulation of antigen presentation machinery expression in breast cancer. , 2018, , .		0
681	Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. , 2008, , 577-592.		0
682	TAMI-05. FATTY ACID SYNTHESIS IS REQUIRED FOR HER2+ BREAST CANCER BRAIN METASTASIS. Neuro-Oncology, 2021, 23, vi199-vi199.	0.6	0
683	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	0.6	0
684	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	0.6	0

#	Article	IF	Citations
685	TMOD-37. IN VIVO COMPRESSION AND IMAGING FOR CAUSAL STUDIES OF MECHANICAL FORCES IN THE BRAIN. Neuro-Oncology, 2020, 22, ii235-ii236.	0.6	0
686	Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment.. Journal of Clinical Oncology, 2022, 40, 610-610.	0.8	0
687	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2022, 40, 485-485.	0.8	0
688	Abstract SY33-01: Improving immunotherapy of cancer by normalizing tumor vessels. , 2019, , .		0
689	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.4	0